We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| TScan Therapeutics Inc | NASDAQ:TCRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.12 | -1.36% | 8.69 | 8.64 | 8.69 | 8.9483 | 8.60 | 8.74 | 22,425 | 15:59:52 |
From May 2023 to May 2024
By Colin Kellaher
TScan Therapeutics shares surged on Tuesday after the clinical-stage biopharmaceutical company said it entered a collaboration potentially worth more than $500 million with biotechnology company Amgen.
Shares of Waltham, Mass.-based TScan were recently changing hands at $3.32, up nearly 48%, in early trading.
TScan said it would receive an upfront payment of $30 million from Amgen, adding that it could earn more than $500 million in success-based milestone payments, along royalty payments on sales of products developed from the collaboration.
TScan and Amgen, based in Thousand Oaks, Calif., said they would work together to discover new targets for the chronic inflammatory bowel disorder Crohn's disease.
TScan ended 2022 with $120 million in cash and equivalents.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 09, 2023 09:53 ET (13:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year TScan Therapeutics Chart |
1 Month TScan Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
